

HEOR Infectious Disease Publications

Conference proceedings

Yu J, Buikema A, Togun A. Using electronic health records to examine HPV vaccine initiation and completion rates. Paper presented at: ISPOR 2018; 2018 May 19-23; Baltimore, MD.

Togun A, **Buikema A, Burton T, McCann E, Tran J.** Chronic kidney disease among patients hospitalized with bacterial infections. Paper presented at: AMCP Nexus 2018; 2018 Oct 22-25; Orlando, FL.

Terrault N, **Tran J, Buikema A, Bancroft T, Ting J, Wong R.** Hepatitis C care cascade among an insured population, 2010-2015: gaps to elimination. Paper presented at: 16th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD); 2018 Jun 14-17; Toronto, Canada.

Sharpsten L, Buikema AR. Epidemiology of meningococcal disease among individuals in a managed care population over a 17-year period (1999-2016). Paper presented at: ISPOR 2018; 2018 May 19-23; Baltimore, MD.

Priest J, **Burton T, Blauer-Peterson C, Andrade K, Oglesby A.** Retrospective analysis of clinical characteristics and treatment patterns among HIV patients with commercial and Medicare Advantage health insurance in the US. Paper presented at: ID Week 2018; 2018 Oct 3-7; San Francisco, CA.

Mujeebuddin S, **Mao J, Bengtson L, Buikema A.** Treatment guidelines and ARV medication initiation in treatment naïve adults, 2008-2016. Paper presented at: ISPOR 2018; 2018 May 19-23; Baltimore, MD.

Krilov LR, Fergie J, Goldstein M, Rizzo C, Brannman L, **McPheeters J**, et al. Severity and costs of respiratory syncytial virus and bronchiolitis hospitalization in commercially insured preterm and term infants before and after the 2014 American Academy of Pediatrics Guidance Change on Immunoprophylaxis. Paper presented at: ID Week 2018; 2018 Oct 3-7; San Francisco, CA.

Eby EL, **Bengtson L, Johnson M, Burton M, Hinnenthal J.** Predictors of cardiac implantable electronic device infection from a large United States healthcare organization. Paper presented at: European Heart Rhythm Association (EHRA) 2018; 2018 Mar 17-19; Lisbon, Portugal. (EP Europace. 2018; 20(S1): 106)

Vutien P, **Tran JN, Cao F, Peichel V, Nguyen MH.** Higher prevalence of existing comorbidities and medication use in untreated patients with chronic hepatitis C (CHC) compared to treated patients: a population-based study in post-oral direct-acting antivirals (DAAs) era. Paper presented at: 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL); 2017 Feb 15-19; Shanghai, China.

Tran J, Song R, Togun A, Buikema A. Carbapenem-resistance in gram-negative organisms using a large US clinical database. Paper presented at: IDWeek 2017; 2017 Oct 4-8; San Diego, CA.

Mao J, MCPheeters J, Finelli L. Herpes zoster incidence, disease burden and cost among patients with solid tumor malignancy receiving chemotherapy 2010-2014 in a large, insured US population. Paper presented at: ISPOR 22nd Annual International Meeting; 2017 May 20-24; Boston, MA.

Mao J, Johnson MP, MCPheeters J, Prajapati G, Beyer A. Healthcare resource utilization and costs of switching first-line antiretroviral therapy among patients with HIV infection in a large, insured US population. Paper presented at: IDWeek 2017; 2017 Oct 4-8; San Diego, CA.

Liou I, Nguyen MH, Lim JK, Shrey S, **Tran J**, et al. Longitudinal changes in renal function and comorbidities in treatment-naïve and treatment-experienced chronic hepatitis B patients in an US insured population: analysis of a real-world cohort with long-term follow-up. Paper presented at: Digestive Disease Week 2017; 2017 May 6-9; Chicago, IL.

Vutien P, **Tran JN, Cao F, Peichel V**, Nguyen MH. Higher prevalence of existing comorbidities and medication use in untreated patients with chronic hepatitis C (CHC) compared to treated patients: a population-based study in post-oral direct-acting antivirals (DAAs) era. Paper presented at: AASLD The Liver Meeting® 2016; 2016 Nov 11-15; Boston, MA.

Goodwin B, **Tran JN, Anderson AJ, Mao J, Cao F**. Antiretroviral treatment patterns in the US: an analysis of real world data. Paper presented at: International Congress of Drug Therapy in HIV Infection 2016; 2016 Oct 23-26; Glasgow, Scotland.

LaMori JC, Forlenza JB, Nelson S, **Cao F**, et al. Sustained virologic response (SVR) and liver disease progression after hepatitis C virus (HCV) treatment initiation: a real world analysis using a large electronic health record (EHR) database. Paper presented at: Digestive Disease Week® (DDW) 2015; 2015 May 16-19; Washington, DC.

Fan W, LaPansee K, **Mao J, Iorga S**, Lodise TP. Direct medical costs and healthcare resource utilization associated with selected antibiotic treatment pathways in acute bacterial skin and skin structure infections in US. Paper presented at: ISPOR 16th Annual European Congress; 2013 Nov 2-6; Dublin, Ireland.

Journal articles

Tandon N, **Mao J**, Shprecher A, et al. Compliance with clinical guidelines and adherence to antiretroviral therapy among patients living with HIV. *Curr Med Res Opin.* 2019;35(1):63-71.

Mao J, McPheeters JT, Zhang D, Acosta CJ, Finelli L. Herpes zoster incidence and cost in patients receiving autologous hematopoietic stem-cell transplant. *Curr Med Res Opin.* 2018;34(4):741-749.

Rosenblatt L, **Buikema AR, Seare J**, et al. Economic outcomes of first-line regimen switching among stable patients with HIV. *J Manag Care Spec Pharm.* 2017 Jul;23(7):725-734.

Puenpatom A, **Hull M, McPheeters J, Schwebke K**. Disease burden, early discontinuation, and healthcare costs in hepatitis C patients with and without chronic kidney disease treated with interferon-free direct-acting antiviral regimens. *Clin Drug Investig.* 2017 Jul;37(7):687-697.

Masseria C, **Martin CK**, Krishnarajah G, **Becker LK, Buikema A**, Tan TQ. Incidence and burden of pertussis among infants less than 1 year of age. *Pediatr Infect Dis J.* 2017 Mar;36(3):e54-e61.

Mao J, McPheeters JT, Finelli L. Healthcare utilization and costs among patients with herpes zoster and solid tumor malignancy on chemotherapy: a retrospective cohort study. *Medicine (Baltimore).* 2017;96(48):e8746.

Goolsby Hunter A, Rosenblatt L, Patel C, **Blauer-Peterson C**, Anduze-Faris B. Clinical characteristics, healthcare costs, and resource utilization in Hepatitis C vary by genotype. *Curr Med Res Opin.* 2017 May;33(5):829-836.

Maiese EM, **Johnson PT, Bancroft T, Goolsby Hunter A**, Wu AW. Quality of life of HIV-infected patients who switch antiretroviral medication due to side effects or other reasons. *Curr Med Res Opin.* 2016 Dec;32(12):2039-2046.

Johnson K, **Brenneman S**, Newransky C, et al. Work and income loss consideration among patients with herpes zoster when completing a quality of life questionnaire. *Value Health.* 2016;19(7):A419.

Masseria C, **Buikema AR, Liu F**, Krishnarajah G. Mixing of diphtheria, tetanus, and acellular pertussis (DTaP) vaccines in a population of children in managed care. *Hum Vaccin Immunother.* 2015 May;11(5):1175-1183.

Jain A, Marshall J, Buikema A, Bancroft T, Kelly JP, Newschaffer CJ. Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. *JAMA.* 2015 Apr 21;313(15):1534-40.

Crown W, Chang J, Olson M, et al. Can statistical linkage of missing variables reduce bias in treatment effect estimates in comparative effectiveness research studies? *J Comp Eff Res.* 2015 Sept;4(5):455-63.

Stewart DL, Ryan KJ, **Seare JG, Pinsky B, Becker L**, Frogel M. Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis. *BMC Infect Dis.* 2013 Jul 19;13:334.

Sato R, **Gomez Rey G, Nelson S, Pinsky B**. Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥ 50 years. *Appl Health Econ Health Policy.* 2013 Jun;11(3):251-8.

Johnson P, Becker L, Halpern R, Sweeney M. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. *Clin Drug Investig.* 2013 Jan;33(1):35-44.

- Gordon SC, Hamzeh FM, Pockros PJ, Hoop RS, **Buikema AR**, et al. Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. *Aliment Pharmacol Ther*. 2013 Oct;38(7):784-793.
- Poordad F, Theodore D, **Sullivan J**, Grotzinger K. Evaluating medical resource utilization and costs associated with thrombocytopenia in chronic liver disease patients. *J Med Econ*. 2012;15(1):112-24.
- Kruzikas D, Smith JS, **Harley C**, **Buzinec P**. Costs associated with management of cervical human papillomavirus-related conditions. *Cancer Epidemiol Biomarkers Prev*. 2012 Sep;21(9):1469-78.
- Krishnarajah G, **Davis EJ**, **Fan Y**, Standaert BA, **Buikema AR**. Rotavirus vaccine series completion and adherence to vaccination schedules among infants in managed care in the United States. *Vaccine*. 2012;30(24):3717-3722.
- Han SH, Jing W, Mena E, Li M, **Pinsky B**, et al. Adherence, persistence, healthcare utilization, and cost benefits of guideline recommended hepatitis B pharmacotherapy. *J Med Econ*. 2012;15(6):1159-66.
- Gordon SC, Pockros PJ, Terrault NA, Hoop RS, **Buikema A**, et al. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. *Hepatology*. 2012 Nov; 56(5): 1651-60.
- Dodds AE, Drew R, Johnson M, Danna R, **Dabroqski D**, et al. Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options. *Pharmacotherapy*. 2012 Oct;32(10):890-901.
- Zimet GD, Stupiansky NW, Weiss TW, Rosenthal SL, **Good MB**, Vichnin MD. Influence of patient's relationship status and HPV history on physicians' decisions to recommend HPV vaccination. *Vaccine*. 2011;29(3):378-381.
- Zimet G, Weiss T, Rosenthal S, **Brenneman S**, Klein J. Physician's sexual health discussions with adolescent males and attitudes about HPV vaccination. *J Adolesc Health Care*. 2011;48(2):S27-28.
- Rosenthal SL, Weiss TW, Zimet GD, Ma L, **Good MB**, Vichnin MD. Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation. *Vaccine*. 2011;29(5):890-895.
- Poordad F, Theodore D, **Sullivan J**, Grotzinger K. Medical resource utilisation and healthcare costs in patients with chronic hepatitis C viral infection and thrombocytopenia. *J Med Econ*. 2011;14(2):194-206.
- McAdam-Marx C, **McGarry LJ**, **Hane CA**, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. *J Manag Care Pharm*. 2011 Sep;17(7):531-46.
- Zimet GD, Weiss TW, Rosenthal SL, **Good MB**, Vichnin MD. Reasons for non-vaccination against HPV and future vaccination intentions among 19-26 year-old women. *BMC Womens Health*. 2010;10:27.
- Weiss TW, Zimet GD, Rosenthal SL, **Brenneman SK**, Klein JD. Human papillomavirus vaccination of males: attitudes and perceptions of physicians who vaccinate females. *J Adolesc Health*. 2010 Jul;47(1):3-11.
- Romero JR, Stewart DL, **Buysman EK**, Fernandes AW, Jafri HS, Mahadevia PJ. Serious early childhood wheezing after respiratory syncytial virus lower respiratory tract illness in preterm infants. *Clin Ther*. 2010 Dec;32(14):2422-2432.
- Stewart DL, Romero JR, **Buysman EK**, Fernandes AW, Mahadevia PJ. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention. *Curr Med Res Opin*. 2009 Nov;25(11):2795-804.
- Siddiqui J, Phillips AL, Freedland ES, **Sklar AR**, **Darkow T**, **Harley CR**. Prevalence and cost of HIV-associated weight loss in a managed care population. *Curr Med Res Opin*. 2009 May;25(5):1307-1317.
- Brixner DI, **Ye X**, Chu TC, Blumentals WA, Hassanein TI. Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin. *Am J Health Syst Pharm*. 2009;66(24):2171-2178.